Phase II study of S-1 plus oxaliplatin (130 mg/m2, every 3 weeks) for advanced gastric cancer
Phase 2
- Conditions
- Advanced gastric cancer
- Registration Number
- JPRN-UMIN000016973
- Lead Sponsor
- Shizuoka Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
1) Massive ascites 2) Massive pleural effusion 3) Evidence of central nervous system metastasis, or clinically suspected 4) Poorly controlled diabetes mellitus 5) Serious lung or cardiovascular disease 6) Active concomitant malignancy 7) Active infection 8) Diarrhea 9) Peripheral neuropathy 10) Blood transfusion, blood products or G-CSF within 21 days at registration 11) Pregnant, nursing or unwilling to practice contraception during the study 12) Severe mental illness
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method